Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets and reassess frequently.
- Plan definitive source control or disease‑specific therapy when indicated; document follow‑up and patient education.
Algorithm
- Treat flare promptly with NSAIDs/colchicine/steroids; rule out septic arthritis when needed.
- Identify indications for ULT; start after flare control; add prophylaxis (colchicine/NSAID) for 3–6 months.
- Titrate ULT to urate target; lifestyle counseling and comorbidity management.
Clinical Synopsis & Reasoning
Treat acute gout with NSAIDs, colchicine, or corticosteroids (intra-articular or systemic). Exclude septic arthritis when uncertain. Start urate-lowering therapy after flares are controlled in patients with tophi, frequent flares, or CKD; provide flare prophylaxis during ULT initiation.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced/procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|
| Arthrocentesis with crystal analysis (if uncertain) | Diagnosis | Negatively birefringent monosodium urate crystals | Exclude infection |
| Serum urate (baseline) | Monitoring | Target <6 mg/dL (<5 if tophaceous) | Guide ULT |
| Renal function and drug interactions | Safety | Dosing/choice constraints | — |
High-Risk & Disposition Triggers
| Trigger | Why it matters | Action |
|---|
| Septic arthritis not excluded | Joint destruction | Arthrocentesis; cultures |
| CKD/anticoagulation | Drug limits | Prefer steroids; adjust colchicine |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|
| NSAIDs (e.g., indomethacin/naproxen) | COX inhibition | Hours | First-line if no contraindications | GI/renal risks |
| Colchicine 1.2 mg then 0.6 mg 1 h later (then 0.6 mg BID) | Microtubule inhibitor | Hours | Early within 36 h | Drug interactions (CYP3A4/P-gp) |
| Corticosteroids (PO/IA/IM) | Anti-inflammatory | Hours | If NSAIDs/colchicine unsuitable | Hyperglycemia risk |
| Allopurinol/Febuxostat for ULT (after flare control) + prophylaxis | XO inhibitors | Days-weeks | Prevent flares and tophi | HLA-B*58:01 in high-risk groups |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.
References
- ACR guideline on gout management — Link